Sun Pharma Advanced Research Company (SPARC) on Thursday said that it has entered a pact with Bioprojet SCR (Bioprojet) to acquire exclusive rights for investigational medicinal product SCD-044.
SCD-044 is a novel investigational oral product, under development for the treatment of auto-immune diseases. Phase I studies for SCD-044 have been completed, SPARC said in a filing to BSE.
"SPARC... announced that it has entered into an agreement with Bioprojet SCR (Bioprojet) to exclusively acquire Bioprojet's rights to the investigational medicinal product SCD-044," the company said.
SPARC and Bioprojet co-owned all SCD-044 related IP, developed through a research collaboration targeting Sphingosine-1-Phosphate Receptors to treat various autoimmune disorders.
The acquisition includes full assignment of all patents and patent applications owned or controlled by Bioprojet related to SCD-044.
Under the terms of the agreement, Bioprojet is eligible to receive milestones and royalties on net sales of SCD-044.
Disclaimer: No Business Standard Journalist was involved in creation of this content
You’ve reached your limit of {{free_limit}} free articles this month.
Subscribe now for unlimited access.
Already subscribed? Log in
Subscribe to read the full story →
Smart Quarterly
₹900
3 Months
₹300/Month
Smart Essential
₹2,700
1 Year
₹225/Month
Super Saver
₹3,900
2 Years
₹162/Month
Renews automatically, cancel anytime
Here’s what’s included in our digital subscription plans
Exclusive premium stories online
Over 30 premium stories daily, handpicked by our editors
Complimentary Access to The New York Times
News, Games, Cooking, Audio, Wirecutter & The Athletic
Business Standard Epaper
Digital replica of our daily newspaper — with options to read, save, and share
Curated Newsletters
Insights on markets, finance, politics, tech, and more delivered to your inbox
Market Analysis & Investment Insights
In-depth market analysis & insights with access to The Smart Investor
Archives
Repository of articles and publications dating back to 1997
Ad-free Reading
Uninterrupted reading experience with no advertisements
Seamless Access Across All Devices
Access Business Standard across devices — mobile, tablet, or PC, via web or app